Wakamoto PharmaceuticalWAKAMOTO PHARMACEUTICAL CO.,LTD.4512東証スタンダード医薬品FY ending Mar 2026, non-consolidated, J-GAAP
Revenue by business segment, and the profit each one keeps.
Geographic revenue reported in annual filings
No geographic revenue breakdown was disclosed.
※ Segment figures include inter-segment sales and do not sum to the company total
X-axis: segment revenue CAGR. Y-axis: latest operating margin. Bubble size: revenue.
Bubble size represents latest revenue. Segments without a CAGR are placed at the left edge; their horizontal position is not a growth value. Color indicates positive or negative margin.
| Segment | Revenue CAGR | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|---|
| Ethical products business-related | -3.2%5y | 4,424-2.6% | 4,460-6.4% | 3,393-22.9% | 3,473-31.3% | 4,762-14.2% |
| Otc products business-Related | +2.1%5y | 1,909-8.2% | 2,00110.7% | 2,45317.6% | 2,34514.1% | 2,54214.5% |
| Sales Development business-Related | — | 1,1625.2% | — | — | — | — |
| Global Sales Development business-Related | +6.3%4y | 1,88610.8% | 2,0197.1% | 1,7185.4% | 1,78913.3% | 2,41020.5% |
| Real estate leasing | +3.5%5y | 16333.7% | 18040.2% | 17433.1% | 18332.1% | 19235.8% |
Top: revenue. Bottom: operating margin.
EDINET (FSA Japan)
有価証券報告書－第131期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第130期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第129期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第128期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第127期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第126期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 47 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.